1-叔丁基-4-氯哌啶 | 5570-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-叔丁基-4-氯哌啶
• 英文名称: 1-tert-butyl-4-chloropiperidine
• 英文别名: 1-tert-butyl-4-chloro-piperidine；1-tert.Butyl-4-chlor-piperidin；N-tert.Butyl-4-chlor-piperidin
• CAS: 5570-81-0
• 化学式: C₉H₁₈ClN
• mdl: MFCD09030849
• 分子量: 175.702
• InChiKey: HWMXPYHJTVUJQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-叔丁基-4-氯哌啶 在 palladium diacetate sodium acetate 、 magnesium 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 反应 5.0h， 生成 1-(2,6-Dichlorophenyl)-1,6-naphthyridin-2-one
  参考文献：
  名称：

  Synthesis of a Naphthyridone p38 MAP Kinase Inhibitor

  摘要：

  Compound 1 is a p38 MAP kinase inhibitor potentially useful for the treatment of rheumatoid arthritis and psoriasis. A novel six-step synthesis suitable for large-scale preparation was developed in support of a drug development program at Merck Research Laboratories. The key steps include a tandem Heck-lactamization, N-oxidation, and a highly chemoselective Grignard addition of 4-(N-tert-butylpiperidinyl)magnesium chloride to a naphthyridone N-oxide. The N-oxide exerted complete chemoselectivity via chelation in directing the Grignard addition to the alpha position as opposed to 1,4- addition on the enelactam. The dihydropyridyl adduct was in situ aromatized with isobutylchloroformate followed by heating in pyridine. Syntheses of Grignard precursor, N-tert-butyl-4-chloro-piperidine, were accomplished via transamination with a quaternary ammonium piperidone or via addition of methylmagnesium chloride to an iminium ion. Utilizing this chemistry, multi-kilogram preparation of compound 1 was successfully demonstrated.

  DOI：

  10.1021/jo061618f
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 在 盐酸 、 氯化亚砜 、 sodium 2-propenoate 、 镍 作用下， 以 乙醇 、 水 、 异丙醇 、 丙酮 为溶剂， 生成 1-叔丁基-4-氯哌啶
  参考文献：
  名称：

  Synthesis of a Naphthyridone p38 MAP Kinase Inhibitor

  摘要：

  Compound 1 is a p38 MAP kinase inhibitor potentially useful for the treatment of rheumatoid arthritis and psoriasis. A novel six-step synthesis suitable for large-scale preparation was developed in support of a drug development program at Merck Research Laboratories. The key steps include a tandem Heck-lactamization, N-oxidation, and a highly chemoselective Grignard addition of 4-(N-tert-butylpiperidinyl)magnesium chloride to a naphthyridone N-oxide. The N-oxide exerted complete chemoselectivity via chelation in directing the Grignard addition to the alpha position as opposed to 1,4- addition on the enelactam. The dihydropyridyl adduct was in situ aromatized with isobutylchloroformate followed by heating in pyridine. Syntheses of Grignard precursor, N-tert-butyl-4-chloro-piperidine, were accomplished via transamination with a quaternary ammonium piperidone or via addition of methylmagnesium chloride to an iminium ion. Utilizing this chemistry, multi-kilogram preparation of compound 1 was successfully demonstrated.

  DOI：

  10.1021/jo061618f

文献信息

• NICOTINE COMPOUNDS AND ANALOGS THEREOF, SYNTHETIC METHODS OF MAKING COMPOUNDS, AND METHODS OF USE
  申请人：Kem William Reade

  公开号：US20130157995A1

  公开（公告）日：2013-06-20

  Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2′substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2 , compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2′substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.

  本公开的实施例提供了化合物，例如图1.1所示的化合物A、B、C和D，2'取代尼古丁化合物，氮杂环化合物，以太键结合的尼古丁化合物（图1.2，化合物E、F、G和H），化合物的合成方法，使用化合物A、B、C、D、2'取代尼古丁化合物、氮杂环化合物或以太键结合的尼古丁化合物治疗疾病的方法，选择性刺激α7 nAChR和/或α4beta2受体的方法等。
• Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
  申请人：Kem William Reade

  公开号：US09440948B2

  公开（公告）日：2016-09-13

  Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2′substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2′substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.

  本公开的实施例提供了如图1.1所示的化合物，例如化合物A、B、C和D，2'-取代尼古丁化合物，氮杂环化合物，以太键结合的尼古丁化合物（如图1.2所示的化合物E、F、G和H），化合物的合成方法，使用化合物A、B、C、D、2'-取代尼古丁化合物、氮杂环化合物或以太键结合的尼古丁化合物治疗疾病的方法，选择性刺激α7 nAChR和/或α4beta2受体的方法等。
• Benzothiophene estrogen receptor modulators
  申请人：G1 Therapeutics, Inc.

  公开号：US10208011B2

  公开（公告）日：2019-02-19

  This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.

  本发明是一种苯并噻吩雌激素受体调节剂或其药学上可接受的盐或其药学上可接受的组合物，用于治疗与雌激素相关的疾病。
• Synthesis of 1-<i>tert</i>-Butyl-4-chloropiperidine:  Generation of an <i>N</i>-<i>tert</i>-Butyl Group by the Reaction of a Dimethyliminium Salt with Methylmagnesium Chloride
  作者：Joseph S. Amato、John Y. L. Chung、Raymond J. Cvetovich、Xiaoyi Gong、Mark McLaughlin、Robert A. Reamer

  DOI：10.1021/jo048047g

  日期：2005.3.1

  Two efficient routes to 1-tert-butyl-4-chloropiperidine are described. In the first route, the key thionyl chloride mediated chlorination reaction features the use of tetrabutylammonium chloride as an additive that effectively suppresses the formation of an elimination-derived side product. In the second route, a novel alternative synthesis of 1-tert-butyl-4-chloropiperidine was developed in which the tertiary butyl group on the nitrogen is efficiently generated through the addition of methylmagnesium chloride to a dimeth-yliminium salt in 71% overall yield.
• CARM1 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20170305922A1

  公开（公告）日：2017-10-26

  Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2a, R2b, R3 and Ring B are as defined herein, and Ring A is a group of Formula (A-i), (A-ii), or (A-iii): wherein R, R, R, R, and R are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.